Table 2.

Summary of Manufacturer Recommendations for Statin and Protease Inhibitor Drug Interactions as Described in Prescribing Information

CYP3A4 InhibitorSimvastatinLovastatinAtorvastatinPravastatinFluvastatinRosuvastatin
AtazanavirNot recommendedNot recommendedUse with cautionClinically significant DIs are not expectedClinically significant DIs are not expectedN/A
NelfinavirNot recommended*Not recommendedUse with cautionConsidered safeConsidered safeN/A
RitonavirNot recommended*Not recommendedUse with cautionConsidered safeConsidered safeN/A
IndinavirNot recommendedNot recommendedUse with cautionConsidered safeConsidered safeConsidered safe
SaquinavirNot recommendedNot recommendedUse with cautionConsidered safeConsidered safeConsidered safe
AmprenavirNot recommendedNot recommendedUse with cautionConsidered safeConsidered safeN/A
FosamprenavirNot recommendedNot recommendedUse with cautionConsidered safeConsidered safeConsidered safe
Lopinavir/ritonavirNot recommendedNot recommendedUse with caution*Considered safeConsidered safeN/A
TipranavirNot recommendedNot recommendedUse with cautionN/AN/AN/A
  • * Rhabdomyolysis has been described.26,28–30

    DI, drug interaction; N/A, interaction not reported.